Vaxart, Inc. (VXRT)
OTCMKTS · Delayed Price · Currency is USD
0.6100
-0.0197 (-3.13%)
At close: Apr 2, 2026
Vaxart Employees
Vaxart had 65 employees as of December 31, 2025. The number of employees decreased by 40 or -38.10% compared to the previous year.
Employees
65
Change (1Y)
-40
Growth (1Y)
-38.10%
Revenue / Employee
$3,650,123
Profits / Employee
$251,185
Market Cap
147.10M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 65 | -40 | -38.10% |
| Dec 31, 2024 | 105 | -4 | -3.67% |
| Dec 31, 2023 | 109 | -55 | -33.54% |
| Dec 31, 2022 | 164 | 54 | 49.09% |
| Dec 31, 2021 | 110 | 82 | 292.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 88 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| Harvard Apparatus Regenerative Technology | 8 |
| Anebulo Pharmaceuticals | 3 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Vaxart News
- 4 weeks ago - Vaxart to Host Upcoming Conference Calls - GlobeNewsWire
- 3 months ago - Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026 - GlobeNewsWire
- 5 months ago - Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program - PRNewsWire
- 5 months ago - Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program - PRNewsWire
- 6 months ago - Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 - GlobeNewsWire
- 7 months ago - Vaxart Appoints W. Mark Watson as Lead Independent Director - GlobeNewsWire
- 7 months ago - Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate - GlobeNewsWire
- 7 months ago - Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting - GlobeNewsWire